Literature DB >> 31804023

Can marine-derived fungus Neosartorya siamensis KUFA 0017 extract and its secondary metabolites enhance antitumor activity of doxorubicin? An in vitro survey unveils interactions against lung cancer cells.

Alice A Ramos1,2, Bruno Castro-Carvalho1,2, Maria Prata-Sena1,2, Fernanda Malhão1,2, Suradet Buttachon3, Tida Dethoup4, Anake Kijjoa1,2, Eduardo Rocha1,2.   

Abstract

Doxorubicin (Dox) is one of the most successful anticancer drugs in use. However, chemoresistance is one of the main limitations that patients face. Therefore, development of new strategies to improve the efficacy of Dox is needed. Marine-derived fungi are especially promising sources of new anticancer compounds. In this work, antitumor activity of crude ethyl extract of the cultures of the marine-derived fungus Neosartorya siamensis KUFA 0017 (NS), combined with Dox, was evaluated in six cancer cell lines. To evaluate possible mechanisms involved in the eventual improvement of Dox's cytotoxicity by NS extract, effects on DNA damage, cell death, ultrastructural modifications, and intracellular accumulation of Dox were assessed. The NS extract demonstrated a significant enhancement of Dox's cytotoxic activity in A549 cells, inducing DNA damage, cell death, and intracellular accumulation of Dox. Additionally, the cytotoxic effect of eight compounds, isolated from this extract, that is, 2,4-dihydroxy-3-methylacetophenone-(C1), nortryptoquivaline-(C2), chevalone C-(C3), tryptoquivaline H-(C4), fiscalin A-(C5), epi-fiscalin-C (C6), epi-neofiscalin A-(C7), and epi-fiscalin A-(C8), alone and combined with Dox was also evaluated in lung cancer cells. The cytotoxic effect of Dox was potentiated by all the isolated compounds (except C1) in A549 cells. Therefore, we concluded that NS extract potentiated cytotoxicity by inhibiting cell proliferation, increasing intracellular accumulation of Dox, and inducing cell death (possibly by an autophagic process). The isolated compounds also enhanced the activity of Dox, supporting the potential of this sort of combination. These data call for further studies to characterize drug interactions and underlying mechanisms.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Neosartorya siamensis; doxorubicin; drug combination; in vitro anticancer activity; marine-derived compounds; marine-derived fungal extract; non-small cell lung cancer

Mesh:

Substances:

Year:  2019        PMID: 31804023     DOI: 10.1002/tox.22886

Source DB:  PubMed          Journal:  Environ Toxicol        ISSN: 1520-4081            Impact factor:   4.119


  5 in total

1.  Decreased complement 4d increases poor prognosis in patients with non-small cell lung cancer combined with gastrointestinal lymph node metastasis.

Authors:  Yan Wang; Mengqi Xiang; Huachuan Zhang; Yongda Lu
Journal:  Exp Ther Med       Date:  2022-07-05       Impact factor: 2.751

2.  Fiscalin Derivatives as Potential Neuroprotective Agents.

Authors:  Sandra Barreiro; Bárbara Silva; Solida Long; Madalena Pinto; Fernando Remião; Emília Sousa; Renata Silva
Journal:  Pharmaceutics       Date:  2022-07-12       Impact factor: 6.525

Review 3.  Potential of Anti-Cancer Activity of Secondary Metabolic Products from Marine Fungi.

Authors:  Efaq Noman; Muhanna Mohammed Al-Shaibani; Muhammed Adnan Bakhrebah; Reyad Almoheer; Mohammed Al-Sahari; Adel Al-Gheethi; Radin Maya Saphira Radin Mohamed; Yaaser Qaeed Almulaiky; Wesam Hussain Abdulaal
Journal:  J Fungi (Basel)       Date:  2021-05-30

4.  Complement sC5b-9 and CH50 increase the risk of cancer-related mortality in patients with non-small cell lung cancer.

Authors:  Jing Li; Zhijun Cao; Lijie Mi; Zhihua Xu; Xiangmei Wu
Journal:  J Cancer       Date:  2020-10-18       Impact factor: 4.207

5.  Chevalones H-M: Six New α-Pyrone Meroterpenoids from the Gorgonian Coral-Derived Fungus Aspergillus hiratsukae SCSIO 7S2001.

Authors:  Xia-Yu Chen; Qi Zeng; Yu-Chan Chen; Wei-Mao Zhong; Yao Xiang; Jun-Feng Wang; Xue-Feng Shi; Wei-Min Zhang; Si Zhang; Fa-Zuo Wang
Journal:  Mar Drugs       Date:  2022-01-14       Impact factor: 5.118

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.